

## NEWS RELEASE

November 27, 2019

### **Methapharm announces the Canadian launch of ARIDOL® (mannitol inhalation powder)**

Methapharm is pleased to announce the Canadian launch of ARIDOL® (mannitol inhalation powder). Methapharm licensed commercial rights to ARIDOL for the US and Canada from Pharmaxis Ltd. of Australia. Methapharm launched ARIDOL in the United States after Pharmaxis received US FDA approval for their manufacturing site in 2018. ARIDOL received Health Canada approval earlier this year.

#### **About Methapharm**

Methapharm is a specialty pharmaceutical company that focuses on the development, acquisition, licensing, and promotion of healthcare products in North America. Methapharm markets its own proprietary products as well as partners with global companies in order to deliver a line of products in the USA and Canada. For more information about Methapharm, please visit [www.methapharm.com](http://www.methapharm.com)

#### **About Pharmaxis**

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please visit [www.pharmaxis.com.au](http://www.pharmaxis.com.au)

###

For more information about Methapharm or business development inquiries, please contact:

Chris Calenti  
Executive Vice President  
Business Development & Licensing  
Tel: (+1) 519.751.3602 x7222

®ARIDOL is a registered trademark of Pharmaxis Ltd, NSW Australia